<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" dms-id="HA1B6FF0D27684A25AA70508CA1873730" public-private="public" key="H" bill-type="olc"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>118 HR 767 IH: Protecting Access to Medication Abortion Act of 2023</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2023-02-02</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">I</distribution-code><congress display="yes">118th CONGRESS</congress><session display="yes">1st Session</session><legis-num display="yes">H. R. 767</legis-num><current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber><action display="yes"><action-date date="20230202">February 2, 2023</action-date><action-desc><sponsor name-id="B001224">Ms. Bush</sponsor> (for herself, <cosponsor name-id="O000173">Ms. Omar</cosponsor>, <cosponsor name-id="S001200">Mr. Soto</cosponsor>, <cosponsor name-id="J000032">Ms. Jackson Lee</cosponsor>, <cosponsor name-id="M001143">Ms. McCollum</cosponsor>, <cosponsor name-id="N000147">Ms. Norton</cosponsor>, <cosponsor name-id="B001292">Mr. Beyer</cosponsor>, and <cosponsor name-id="C001072">Mr. Carson</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name></action-desc></action><legis-type>A BILL</legis-type><official-title display="yes">To preserve access to abortion medications.</official-title></form><legis-body id="H6A8D69D542EB48A6B0504D7AE39549F6" style="OLC"><section section-type="section-one" id="H89FDAA9EB0014E4796174B12B5E3C79B"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Protecting Access to Medication Abortion Act of 2023</short-title></quote>.</text></section><section id="HAAD5B53BF91246B6B03F85A1FDE0161B"><enum>2.</enum><header>Modification of REMS</header><subsection id="H6BF7E90D12644AD4B02D0A369E3E14A3"><enum>(a)</enum><header>In general</header><text display-inline="yes-display-inline">The Secretary of Health and Human Services (referred to in this section as the <quote>Secretary</quote>) shall ensure that the risk evaluation and mitigation strategy under section 505–1 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355-1">21 U.S.C. 355–1</external-xref>) that applies to mifepristone—</text><paragraph id="H8F12BDCC89F44B7AB24DB73926DD7669"><enum>(1)</enum><text display-inline="yes-display-inline">does not have an in-person dispensing requirement for such drug; </text></paragraph><paragraph id="H72734A138AED4E1DA22C6B47DECE2135"><enum>(2)</enum><text display-inline="yes-display-inline">allows for patient access to prescriptions for such drug via telehealth; and</text></paragraph><paragraph id="HC2654203FDBD4D8782E9AAD78A115EFF"><enum>(3)</enum><text>allows all pharmacies that are certified to dispense such drug to, at minimum, dispense and mail such drug to patients.</text></paragraph></subsection><subsection id="HDD828FC521C9412CA50971513F81836D"><enum>(b)</enum><header>Modifications</header><text>Nothing in subsection (a) shall be construed to prevent the Secretary from approving a modification to the risk evaluation and mitigation strategy for mifepristone based on sound scientific evidence and in accordance with section 505–1(h) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355-1">21 U.S.C. 355–1(h)</external-xref>), except that any modifications to such risk evaluation and mitigation strategy made after January 3, 2023, shall be in accordance with the requirements under paragraphs (1), (2), and (3) of subsection (a), unless the Secretary, based on sound scientific evidence and in accordance with section 505–1 of such Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355-1">21 U.S.C. 355–1</external-xref>), determines that a risk evaluation and mitigation strategy for mifepristone is no longer necessary. </text></subsection><subsection id="HCDBE569DA08D462B8243B1FC3FC3C084"><enum>(c)</enum><header>Clarification</header><text>Nothing in subsection (a) shall be construed to limit the authority of the Secretary to impose the requirements described in paragraphs (1), (2), and (3) of such subsection to a risk evaluation and mitigation strategy under section 505–1 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355-1">21 U.S.C. 355–1</external-xref>) for any drug other than mifepristone. </text></subsection><subsection id="H306D74699D204AECB59D2FEB8E3939EB"><enum>(d)</enum><header>Definition</header><text>In this section, the term <term>mifepristone</term> means mifepristone that is—</text><paragraph id="H9A6FE891166745298D9CB460B55EBCEA"><enum>(1)</enum><text>approved under subsection (c) or (j) of section 505 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355</external-xref>);</text></paragraph><paragraph id="HAD024224BD5E47F8AEF92ED95FCE811E"><enum>(2)</enum><text>indicated for medical abortion; and</text></paragraph><paragraph id="HDF96EBAF34FB4F658EE42615CA64B768"><enum>(3)</enum><text>subject to a risk evaluation and mitigation strategy under section 505–1 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355-1">21 U.S.C. 355–1</external-xref>).</text></paragraph></subsection></section></legis-body></bill> 

